Mourabit Halima, Author at MediaMedic

BOC/BOA 2024丨Professor Chaosu Hu: Advances in Immunotherapy and Proton Carbon Ion Therapy for Head and Neck Tumors

By Mourabit Halima 2024.07.19

Traditional treatment for head and neck tumors mainly involves surgery, radiotherapy, and chemotherapy. In recent years, immune checkpoint inhibitors have shown promising potential in treating head and neck squamous cell carcinoma, and new radiotherapy techniques such as proton and carbon ion therapy offer treatment options with reduced radiation toxicity for patients with head and neck tumors. At the recent 2024 BOC/BOA conference, Professor Chaosu Hu from Fudan University Shanghai Cancer Center chaired the head and neck tumor session, sharing and discussing significant research findings from the 2024 ASCO conference with colleagues. Oncology Frontier interviewed Professor Hu at the BOC/BOA conference to further explore the current diagnosis and treatment status and research progress in head and neck tumors.

Professor Uwe Platzbecker: Breakthrough Progress in the Treatment of Acute Promyelocytic Leukemia (APL) — Key Findings from the APOLLO Study

By Mourabit Halima 2024.07.19

Acute promyelocytic leukemia (APL) is a highly aggressive blood disorder, and its treatment has always been a challenge in the field of hematology. Chinese scholars have contributed the arsenic trioxide (ATO) regimen for global APL patients. Since the APL0406 study reported in the New England Journal of Medicine in 2013, all-trans retinoic acid (ATRA) combined with ATO has replaced ATRA combined with chemotherapy as the standard treatment for patients with intermediate and low-risk APL. However, whether this regimen is suitable for high-risk APL patients is still lacking in randomized controlled trial reports. At the 29th Annual Congress of the European Hematology Association (EHA 2024) held from June 13 to 16, 2024, Professor Uwe Platzbecker from Leipzig University in Germany presented the key results of the APOLLO study in an oral report. The study showed that the combination of ATO and ATRA provides a new treatment strategy for high-risk APL patients, offering valuable insights into the current state of APL treatment and guiding future research directions and clinical practices. "Oncology Frontier-Hematology Frontier" specially invited Professor Platzbecker on-site to share the important findings and clinical significance of the APOLLO study.

BOC/BOA 2024丨New Breakthroughs in ADC Drugs for Breast Cancer Treatment—Professor Ying Fan Interprets the DB-06 and OptiTROP-Breast01 Studies

By Mourabit Halima 2024.07.19

In the field of breast cancer treatment, the rapid development of antibody-drug conjugates (ADCs) is gradually changing the traditional treatment landscape, bringing more hope to patients. The presentation of the DB-06 and OptiTROP-Breast01 studies at the 2024 ASCO conference has elevated the application of ADC drugs in breast cancer treatment to a new level. At the 2024 BOC/BOA conference, Oncology Frontier invited Professor Ying Fan from the Cancer Institute & Hospital Chinese Academy of Medical Sciences to provide an in-depth interpretation of these two research advances and discuss the latest developments in ADC drug treatment for HER2-low breast cancer and triple-negative breast cancer (TNBC).

First Immunotherapy Combined with ADC Neoadjuvant Treatment for MIBC Revealed, Meeting the Survival Needs of More Patients

By Mourabit Halima 2024.07.18

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 31 to June 4 in Chicago, USA, showcasing numerous cutting-edge research findings that will further advance the diagnosis and treatment practices in the field of urological tumors. Among them, a multicenter Phase II clinical study conducted in China, led by Peking University Cancer Hospital, on disitamab vedotin (RC48) combined with toripalimab for neoadjuvant treatment of muscle-invasive bladder cancer (MIBC) with HER2 expression has been included (Abstract No. 4568). "Oncology Fron

BOC/BOA 2024丨Professor Yu Chen: Exploring New Strategies for Melanoma Treatment and Tackling Immunotherapy Resistance

By Mourabit Halima 2024.07.18

Melanoma is one of the more common malignant tumors clinically. In recent years, although immunotherapy has brought new hope to melanoma patients, the issue of resistance has become increasingly prominent. At the 2024 Annual Progress Seminar of Chinese Clinical Oncology (BOC) and Beast of ASCO® 2024 China (BOC/BOA 2024), Professor Yu Chen from Fujian Cancer Hospital shared the latest research achievements in the field of melanoma treatment. In an exclusive interview with Oncology Frontier, Professor Chen further discussed the mechanisms of immunotherapy resistance and explored the potential of various individualized treatment plans to overcome resistance.

Professor Pei Dong: Continuously Exploring Individualized Treatment Strategies for Advanced Kidney Cancer in China

By Mourabit Halima 2024.07.18

Kidney cancer is one of the three major tumors of the urinary system. According to statistics, in 2022, there were approximately 77,000 new cases and 46,000 deaths from kidney cancer in China. The prognosis for advanced metastatic kidney cancer is poor, with a five-year overall survival rate of less than 20% with targeted therapy alone. As research progresses both domestically and internationally, the treatment of advanced kidney cancer is continuously improving. At this year’s Annual Progress Seminar of Chinese Clinical Oncology (BOC) and Best of ASCO 2024 China (BOC/BOA 2024) held in Guangzhou, Oncology Frontier invited Professor Pei Dong from Sun Yat-sen University Cancer Center to share insights on the unmet needs for advanced kidney cancer in China, the latest treatment advancements both domestically and internationally, and the future changes in clinical practice.

Prophylactic Infusion of Donor-Derived CD7 CAR-T Cells Post-Allo-HSCT for Treating R/R T-ALL/LBL

By Mourabit Halima 2024.07.18

Recent clinical studies have shown that CD7-targeted chimeric antigen receptor T-cell (CAR-T) therapy is effective and safe for patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL). Combining CAR-T therapy with transplantation has the potential to enhance treatment efficacy and reduce disease recurrence. Most existing studies have implemented CD7 CAR-T cells as a bridge to allogeneic hematopoietic stem cell transplantation (allo-HSCT). Recently, Professor Chun Wang’s team at Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital successfully applied a new approach: post-allo-HSCT infusion of donor-derived CD7 CAR-T cells to treat a case of refractory T-ALL/LBL. This study, published in Frontiers in Immunology, offers new strategies for treating R/R T-ALL/LBL patients. We conducted an exclusive interview with the study's first author, Professor Ying Jiang, to provide a deeper understanding of this research.

EHA Expert Interview | Three Studies from Professor Sanbin Wang’s Team Selected for EHA: An In-Depth Review

By Mourabit Halima 2024.07.18

The 29th European Hematology Association (EHA) Annual Congress was held in Madrid, Spain, from June 13 to 16, 2024. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars worldwide to share and discuss innovative ideas and the latest scientific and clinical research achievements in hematology. At this year's EHA Congress, three studies from Professor Sanbin Wang's team at The 920th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army were selected as posters (abstracts P544, 965, and 420), exploring treatment advancements in AML, RRMM, and r/r B-ALL, respectively. Oncology Frontier-Hematology Frontier invited Professor Sanbin Wang to share and interpret the content and significance of these studies.

BOC/BOA 2024丨Professor Xiaojie Bian: Radioligand Therapy & PROTAC Treatment Bring New Hope for mCRPC

By Mourabit Halima 2024.07.18

From July 5 to 7, 2024, the 2024 Annual Progress Seminar of Chinese Clinical Oncology (BOC) and Beast of ASCO® 2024 China (BOC/BOA) was grandly held in Guangzhou. On the 6th, Professor Xiaojie Bian from Fudan University Shanghai Cancer Center shared the latest drug development progress for metastatic castration-resistant prostate cancer (mCRPC) from the 2024 ASCO annual meeting in the urologic tumor session, showcasing the new radioligand drug JNJ-6420 and the PROTAC AR-766.

Embrace the synergy of global expertise and local insights with Professor Zefei Jiang at the 2024 Best of ASCO/Best of CSCO.

By Mourabit Halima 2024.07.18

As the Vice Chairman and Secretary-General of the Chinese Society of Clinical Oncology (CSCO), he leads the charge in aligning Chinese clinical oncology with international standards. Experience the cutting-edge advancements in targeted therapies, immunotherapies, and the integration of precision medicine. Let's innovate together for a future where cancer treatment knows no borders.